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Background: The existence of a dichotomy between immunologically active and quiescent
tumor phenotypes has been recently recognized in several types of cancer. The activation
of a Th1 type of immune signature has been shown to confer better prognosis and likeli-
hood to respond to immunotherapy. However, whether such dichotomy depends on the
genetic make-up of individual cancers is not known yet. BRAF and NRAS mutations are
commonly acquired during melanoma progression. Here we explored the role of BRAF
and NRAS mutations in influencing the immune phenotype based on a classification pre-
viously identified by our group.
Methods: One-hundred-thirteen melanoma metastases underwent microarray analysis and
BRAF and NRAS genotyping. Allele-specific PCR was also performed in order to exclude
low-frequency mutations.
Results: Comparison between BRAF and NRAS mutant versus wild type samples identified
mostly constituents or regulators of MAPK and related pathways. When testing gene lists
discriminative of BRAF, NRAS and MAPK alterations, we found that 112 BRAF-specific tran-
scripts were able to distinguish the two immune-related phenotypes already described in
melanoma, with the poor phenotype associated mostly with BRAF mutation. Noteworthy,search Center, Al Nasr Tower, Al Corniche Street, Qatar Foundation, PO 26999, Doha, Qatar.
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MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 9 3e1 0 494such association was stronger in samples displaying low BRAFmRNA expression. However,
when testing NRAS mutations, we were not able to find the same association.
Conclusion: This study suggests that BRAF mutation-related specific transcripts associate
with a poor phenotype in melanoma and provide a nest for further investigation.
ª 2014 The Authors. Published by Elsevier B.V. on behalf of Federation of European
Biochemical Societies. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction signatures according to the immunological phenotypesMalignant cutaneous melanoma is an aggressive neoplasm
characterized by a complex etiology that challenges targeted
therapies (Gray-Schopfer et al., 2007; Hocker et al., 2008;
Nikolaou et al., 2012; Tomei et al., 2014). Several molecular al-
terations occur during melanoma progression. The most
commonly mutated pathway is the mitogen-activated protein
kinases (MAPK)/ERK cascade (Dhomen and Marais, 2009;
Palmieri et al., 2009). The critical role of MAPK/ERK activation
in melanoma development has prompted attempts to exploit
this pathway as a therapeutic target (Ascierto et al., 2012;
Frankel et al., 2003; Ibrahim and Haluska, 2009; Karasarides
et al., 2004; Zambon et al., 2012). The activation of the
MAPK/ERK signaling occurs either through gain-of-function
mutations in the BRAF and NRAS genes or through autocrine
growth factor stimulation (Curtin et al., 2005; Edlundh-Rose
et al., 2006; Satyamoorthy et al., 2003; Smalley, 2003).
Documented mutations have been found in the kinase
domain of BRAF, encoded by exons 11 and 15 (Brose et al.,
2002; Davies et al., 2002) with a frequency of 50e70% (Davies
et al., 2002). Themajority of thesemutations affect one critical
amino acid, resulting in the V600E substitution that leads to
constitutive kinase activation of BRAF (Davies et al., 2002).
The V600E mutation, accounting for more than 90% of all
BRAF mutations, is associated with an over 400-fold greater
basal activity as compared to wild type BRAF (Davies et al.,
2002; Kumar et al., 2004; Pollock et al., 2003).
In some melanomas without BRAF mutation, the MAPK/
ERK pathway is constitutively activated through mutation of
NRAS (van Elsas et al., 1996). Activating mutations in NRAS,
mostly at codon 61, have been identified in about 15% of mel-
anomas (Curtin et al., 2005) and result in the reduction of
intrinsic GTPase activity and in the constitutive activation of
NRAS.
Both functional and genetic studies indicate that BRAF and
NRAS act linearly in the signaling pathway, which is demon-
strated by the almost mutually exclusiveness of mutations
in these genes and the consequent downstream activation.
Although the oncogenic potential of BRAF and NRAS alter-
ations has been attributed to reduced apoptosis, increased
invasiveness and increased metastatic behavior (Gray-
Schopfer et al., 2005; Maurer et al., 2011), the role of BRAF
and NRAS in the immunological landscape of cutaneous mel-
anoma has been poorly investigated and the effects of BRAF
and NRAS mutations on global gene expression remain to be
understood. A few studies have attempted to test whether a
BRAF and NRAS mutation-associated gene expression signa-
ture exists in melanoma but none of them evaluated such(Bittner et al., 2000; Johansson et al., 2007; Kannengiesser
et al., 2008; Pavey et al., 2004; Schramm et al., 2012). Relevant
in this context, gene expression signatures have been shown
to predict response to anticancer immunotherapy (Ulloa-
Montoya et al., 2013; Wang et al., 2013a).
Emerging data is now revealing the existence of at least
two different immune phenotypes in melanoma, a Th17
phenotype associated with the over-expression of WNT5A,
enhanced cellular motility, a more undifferentiated status
and poor prognosis, and a Th1 immune phenotype associated
with the expression of melanocytic lineage specific tran-
scripts, a higher responsiveness to immune cytokines, a
more differentiated status and better prognosis (Bittner
et al., 2000; Murtas et al., 2013; Spivey et al., 2012). The exis-
tence of similar phenotypes has also been shown in colorectal
cancer where type, density and location of immune cells have
been found to predict patient survival (Galon et al., 2013).
It is not yet, however, clear whether the existence of these
two different phenotypes depends upon the genetic back-
ground of the host or is dictated by the genetics of the tumor
or both (Wang et al., 2013b, 2012). The finding that selective
BRAF inhibitors inducemarkedTcell infiltration, enhancemel-
anomaantigenexpressionand improve theanti-tumoractivity
of adoptive immunotherapy in mice (Tompers Frederick et al.,
2013; Viros et al., 2008; Wilmott et al., 2012) emphasizes the
need to study this link. Moreover BRAF and NRAS activating
mutationshavebeenassociatedwith theproductionof various
immunosuppressive factors in melanoma cell lines (Castelli
et al., 1994; Sumimoto et al., 2006). Furthermore, a recent study
demonstrates that re-activation of MAPK signaling provides a
mechanism of therapeutic resistance via modulation of host
immune responses (Devitt et al., 2011). Most relevant to our
work, Khalili et al. recently showed that the BRAFV600Emuta-
tion promotes stromal cell-mediated immunosuppression via
induction of IL-1 (Khalili et al., 2012), highlighting the immuno-
suppressive role of BRAF in melanoma.
We recently proposed a genetic classification of melanoma
metastases based on copy number variation and consistency
of genes expressed in vivo and in vitro (Spivey et al., 2012). We
found that genes consistently expressed by 15 melanoma cell
lines (CMs) and their parental tissues (TMs) were critical for
oncogenesisand their respectivecopynumber influenced their
expression.Most importantly, these geneswere able to catego-
rize melanoma metastases into two divergent phenotypes
(TARA class: transcriptional adjustments related to amplification/
deletions): one with prevalent expression of cancer testis anti-
gens, enhanced cyclin activity, WNT signaling, and a Th17 im-
mune phenotype (Class A) and the other one with prevalent
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with a Th1 immunephenotype (Class B). An intermediate third
class (C) was further identified. The 3 phenotypes were
confirmed by unsupervised principal component analysis.
Here, we tested whether these phenotypes might be at least
in part explained by BRAF and NRAS mutations in melanoma.
We found that BRAF mutation-related specific transcripts
associate with the poor melanoma phenotype and such asso-
ciation resulted particularly strong in BRAF mutant tumors
displaying low expression levels of this gene.
Our findings strongly suggest a role of BRAF mutation and
mRNA expression in influencing the immune phenotypes in
melanoma.2. Materials and methods
2.1. Specimens
One-hundred-thirteen pre-treatment snap frozen tumor bi-
opsies were collected from patients treated at the Surgery
Branch, National Cancer Institute, Bethesda, Maryland, who
underwent adoptive immunotherapy with tumor infiltrating
lymphocytes and myeloablative conditioning. Fifteen mela-
noma cell lines were derived from as many metastatic mela-
nomas. Identity confirmation of cell lines and parental
tissues was carried out by HLA phenotyping as previously
described (Spivey et al., 2012).
2.2. BRAF and NRAS genotyping
Genomic DNA was isolated using QIAamp DNA Mini Kit (Qia-
gen, Germantown, MD) and phenol/chloroform method from
cell lines and tumor tissues, respectively and according to
the standard protocols. DNA quality and quantity was esti-
mated using Nanodrop (ThermoScientific, Pittsburgh, PA).
Each sample was screened for mutations in exons 11 and
15 for BRAF gene and exon 1 and 2 for NRAS gene. PCRwas per-
formed in 20 ml final volume, containing 50 ng of genomic
DNA, 10 ml of Qiagen HotStarTaq Master Mix Kit (Valencia,
CA) and 500 nM forward and reverse primers with the
following cycling conditions: initial denaturation at 95 C for
10 min; 35 cycles at 95 C for 30 s, 56 C for 30 s and 72 C for
30 s; final step 72 C for 10 min. Primers were selected using
Primer3 software (http://frodo.wi.mit.edu/):
BRAF_ex11_F: 50-TCCCTCTCAGGCATAAGGTAA-30
BRAF_ex11_R: 50-CGAACAGTGAATATTTCCTTTGAT-30
BRAF_ex15_F: 50-TCATAATGCTTGCTCTGATAGGA-30
BRAF_ex15_R: 50-GGCCAAAAATTTAATCAGTGGA-30
NRAS_ex1_F: 50-CACTAGGGTTTTCATTTCCATTG-30
NRAS_ex1_R: 50-TCCTTTAATACAGAATATGGGTAAAGA-30
NRAS_ex2_F: 50-ATAGCATTGCATTCCCTGTG-30
NRAS_ex2_R: 50-CACAAAGATCATCCTTTCAGAGA-30
In each PCR reaction distilled water was used as a negative
control.
PCR products were purified with Exosap-IT (USB Corpora-
tion, Cleveland, OH) and labeled using Big Dye terminator kit
v3.1 (Applied Biosystems, Foster City, CA). Excess dye termina-
tors were removed using DyeEx 96 Kit columns following the
manufacturer’s instructions (Qiagen). Sequencing was thenperformed using Biosystems 3730 Genetic Analyzer (Foster
City, CA) and analyzed by Sequencher software (Genecodes,
Ann Arbor, MI).
2.3. BRAF and NRAS allele-specific PCR (AS-PCR)
AS-PCR for the detection of BRAF V600E andNRASQ61R, Q61K,
Q61L and Q61Hmutations was conducted as described above.
Primers were designed to possess two bases substitution at 30-
end compared towild type sequences, as previously published
(Linard et al., 2002; Sensi et al., 2006). These primers were,
respectively:
BRAF15_R: 50-GGCCAAAAATTTAATCAGTGGA-30
BRAF15_WT_F: 50-TAGGTGATTTTGGTCTAGCTACAGT-30
BRAF15_V600E_F: 50-GGTGATTTTGGTCTAGCTACAAA-30
NRAS2_R: 50-TGACTTGCTATTATTGATGG-30
NRAS2_WT_F: 50-CATACTGGATACAGCTGGAC-30
NRAS2_Q61K_F: 50-CATACTGGATACAGCTGGGA-30
NRAS2_Q61R_F: 50-ATACTGGATACAGCTGGAAG-30
NRAS2_Q61L_F: 50-ATACTGGATACAGCTGGATT-30
NRAS2_Q61H1_F: 50-TACTGGATACAGCTGGACTT-30
NRAS2_Q61H2_F: 50-TACTGGATACAGCTGGACTC-30
Cycling conditions were as following: initial denaturation
at 95 C for 10 min; 40 cycles at 95 C for 30 s, 54 C for 30 s
and 72 C for 45 s; final step 72 C for 10 min. PCR products
were run on 2% agarose gel.
2.4. Microarray analysis
Total RNA from the 15 cell lines and 113melanomametastases
was isolated usingmiRNeasyminikit (Qiagen) according to the
manufacture’s protocol (Bedognetti et al., 2013; Spivey et al.,
2012). RNA quality and quantity was estimated using Nano-
drop (Thermo Scientific) and Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA). First- and second-strand
cDNAswere synthesized from 300 ng of total RNA according to
manufacturer’s instructions (Ambion WT Expression Kit).
cDNAs were fragmented, biotinylated, and hybridized to the
GeneChip HumanGene 1.0 ST Arrays (Affymetrix, Santa Clara,
CA). The arrays were washed and stained on a GeneChip Flu-
idics Station 450 (Affymetrix). Scanning was carried out with
the GeneChip Scanner 3000 and image analysis with the Affy-
metrix GeneChip Command Console Scan Control. Expression
data were normalized, background-corrected, and summa-
rized using the robust multichip average (RMA) algorithm,
http://www.partek.com/. Data were log2 transformed for sub-
sequent statistical analysis. For the external validation,
GSE22155 array data were downloaded from GEO (http://
www.ncbi.nlm.nih.gov/geo/) and log2 transformed. Hierarchi-
cal clustering and PCA analyses were performed using Partek
software (Partek Inc., St. Louis, MO, USA).
2.5. BRAF siRNA (small interference) in melanoma cell
lines
Melanoma cell lines were assigned to “high” and “low” groups
based on the BRAF average expression. The “high” cell lines
were further selected for BRAF RNA interference experiment.
Control siRNA (siGENOME Non-Targeting siRNA Pool #1, D-
001206-13-05), BRAF siRNA (SMARTpool siGENOME BRAF
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 9 3e1 0 496siRNA, M-003460-03-0005) and DharmaFECT 1 Transfection
Reagent (T-2001-01) were purchased from Thermo Fisher
Scientific-Dharmacon (Pittsburgh PA, USA).
Melanoma cell lines were seeded in 6-well plates at
5  105 cells/well and the day after transfected with BRAF or
Control siRNA using DharmaFECT 1 Transfection Reagent
(final siRNA concentration, 50 nM) following the manufac-
turer’s instructions. Forty-eight hour after transfection, cells
were collected and total RNA was extracted using Trizol (Invi-
trogen e Life Technologies Carlsbad, CA, USA). One mg of total
RNA was reverse-transcribed in cDNA using SuperScript III
(Invitrogen e Life Technologies) according to the manufac-
turers’ directions. Four genes associated to the Th1 and Th17
based on a previous report (Spivey et al., 2012) were selected
for gene expression analysis, namely STAT1, GBP1 IL17A and
IL17B. Quantitative Real Time-PCR (qPCR) was performed on
an AB ViiA 7 real-time PCR system (Applied Biosystems e
Life technologies, Grand Island, NY, USA) using TaqMan
gene expression assays (Applied Biosystems e Life Technolo-
gies) with the following probes: Hs00269944_m1 for BRAF,
Hs01013996_m1 for STAT1, Hs00977005_m1 for GBP1,
Hs00174383_m1 for IL17A and Hs00975262_m1 for IL17B.
Biological samples were run in quadruplicate. The endoge-
nous reference gene 18S was used to normalize each gene
expression level and as internal reference (Eukaryotic 18S
rRNA Endogenous Control, 4310893E, Applied Biosystems e
Life Technologies). For each qPCR experiment, a no-template
reaction was included as negative control. The thermal
cycling conditions were as follows: initial denaturing at
95 C for 10 min, 40 cycles of 95 C for 15 s and 60 C for
1 min. For each gene, the fold difference between control
siRNA- and BRAF siRNA-transfected melanoma cell lines
was calculated using the comparative 2eDDCt method.2.6. Statistical analyses
To identify transcripts whose expression was associated with
BRAF and NRAS mutational status we performed class com-
parison of BRAF mutated versus BRAF and NRAS wild typeTable 1 e BRAF and NRAS mutational status of cell lines and
matched tumors.
Tumor BRAF NRAS Cell line BRAF NRAS
SAR-32 V600E wt 2492 V600E wt
SAR-38 V600E wt 2448 V600E wt
SAR-39 V600E wt 3104 V600E wt
SAR-58 V600E wt 2523 V600E wt
SAR-59 V600E wt 2224 V600E wt
SAR-89 V600E wt 2035 V600E wt
SAR-52 wt Q61K 2075 wt Q61K
SAR-77 wt Q61L 3107 wt Q61L
SAR-17 wt Q61R 2744 wt Q61R
SAR-33 wt Q61R 2155 wt Q61R
SAR-102 wt Q61R 1866 wt Q61R
SAR-121 wt wt 2805 wt wt
SAR-63 wt wt 2458 V600E wt
SAR-78 wt wt 3025 V600E wt
SAR-21 wt wt 2427 wt Q61R
wt: wild type.samples and NRAS mutated versus BRAF and NRAS wild
type samples. Class comparisonwas based on analysis of vari-
ance (ANOVA). Principal component analysis (PCA) was
applied for visualization when relevant. Heat maps are pre-
sented based on Partek visualization program. Fisher’s exact
and c2 tests were used as appropriate. All statistical tests
were two-sided. We used relatively low-stringency class com-
parison for subsequent enrichment analysis (Bedognetti et al.,
2011). Functional gene network analysis was performed using
the Ingenuity Pathway Analysis system (IPA) tools 3.0 which
transforms large data sets into a group of relevant networks
containing direct and indirect relationships between genes
based on known interactions in the literature (http://www.in-
genuity.com, Ingenuity System Inc., Redwood City, CA, USA).3. Results
3.1. BRAF and NRAS mutations in cell lines and tumors
Eight out of fifteen (53%) cell lines and sixty-seven out of one-
hundred-thirteen (59%) tumors harbored a BRAF mutation.
Most of the mutations (8/8 in cell lines and 64/67 in tumors)
were the classical V600E substitution. Three samples carried
K601E, V600K and V600R mutations, respectively. Among the
seven cell lines and forty-six tumors that did not display a
BRAF mutation, six cell lines and thirteen tumors harbored
activating mutation in NRAS gene (four cell lines displayed
Q61R, two cell lines displayed Q61K and Q61L respectively;
among tumors, NRAS mutations were: eight Q61R, two
Q61K, and three Q61L, Q61H and G13R respectively). BRAF
and NRAS mutations were mutually exclusive both in cell
lines and tumors.
Interestingly, when comparing BRAF and NRASmutational
status in cell lines and matched parental tumors, three pairs
were discordant.3.2. AS-PCR (allele-specific PCR) revealed low frequency
BRAF and NRAS mutations
To exclude the possibility that BRAF and NRAS mutations
could exist at low frequency in melanoma, we probed the
samples with a highly sensitive allele-specific PCR
(Supplementary Figure 1).
When comparing the BRAF and NRAS mutational status of
cell lines and parental tumors after applying AS-PCR, we inter-
estingly found that the two tumors whose corresponding cell
line was BRAF V600E actually resulted mutated by AS-PCR
(Table 1). However, the NRAS Q61R tumor whose correspond-
ing cell line was wild type remained wild type after applying
AS-PCR, suggesting that in this specific case the mutation
might have been acquired during cell culturing.
We next tested the presence of BRAF and NRAS low fre-
quency mutations in the wild type tumors as well by applying
AS-PCR. Among the 33 BRAF and NRAS wild type samples, 12
turned out to be BRAF V600E and 1 NRAS Q61R-mutated. We
thus considered these samples as low frequency-mutants
and excluded them from further expression data analyses.
However, we decided to keep them for the graphical analyses.
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expression in tumors
To test whether BRAF and NRAS mutations affect the tran-
scriptome of the 113 metastases, we applied PCA to the com-
plete data set. The assignment of the individual metastases to
BRAF, NRAS and wild type groups did not predict their distri-
bution in three-dimensional space suggesting that BRAF and
NRAS mutations do not directly affect gene expression at
global level (Figure 1a).
Gene expression data were next used to identify genes
discriminating the 113 tumors between mutated and wild
type for both BRAF and NRAS. At a significance level of
p< 0.01, 583 transcripts were differentially expressed between
BRAFmutant versus wild type samples (Figure 1b) and 186 be-
tween NRAS mutant versus wild type samples (Figure 1c).
Notably, when assessing genes concordantly deregulated in
both BRAF and NRAS mutant samples, it was found that
most encoded constituents or regulators of the MAPK/ERK
and related pathways.
In accordance with the findings of other groups (Bloethner
et al., 2005; Khalili et al., 2012; Packer et al., 2009), the top
ranking genes with a potential role, direct or indirect, in the
MAPK/ERK pathway included the dual specificity phosphatase
genes, DUSP6 and DUSP4; an inhibitor of MAPK signaling,
SPRY2; a serine protease inhibitor, SERPINE2; and genes of
the 14-3-3 family.Figure 1 e Principal component analysis of BRAF and NRAS mutations b
metastases based on genes discriminative of BRAF (b), NRAS (c) and MA3.4. BRAF mutation associates with the poor phenotype
in melanoma
We next tested whether genes discriminative of BRAF and
NRAS mutational status were able to distinguish different
immunological phenotypes. Towards this goal, we used a ge-
netic classificationwhich has been identified by our group in a
previous study (Spivey et al., 2012) and which we refer to as
TARA (“transcriptional adjustments related to amplification/
deletions”). Five TARA classes of melanoma metastases were
defined according to the clustering based on genes concor-
dantly expressed in vivo and in vitro and whose expression
was also predicted by the corresponding copy number
(Supplementary Figure 2, Supplementary Table 1). Class A
and Aa referred to an unfavorable immune phenotype associ-
ated with a Th17 activation and bad prognosis while class B
and Bb referred to a more favorable phenotype associated
with a Th1 activation and better prognosis. A third category
sitting astride the two polar groups was also identified (Class
C). It should be stated that the classification used in this paper
differs from the already published one in the number of TARA
classes defined. Contrary to our previous study (Spivey et al.,
2012), we used 5 instead of 3 TARA classes. As the extreme
classes “A” and “B” previously identified showed a gradient
in the expression of the geneswhose transcriptional efficiency
was predicted by the corresponding copy number, we thought
that it would have been more appropriate stratifying all theased on the complete gene dataset (a). Clustering of melanoma
PK (d) status at p< 0.01.
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map based on the top 500 genes obtained when comparing
TARA A versus TARA B, as shown in the Supplementary
Figure 2.
When we used the genes discriminative of BRAF and NRAS
status to cluster the melanoma metastases, we observed that
BRAF-discriminative genes clearly segregate samples accord-
ing to TARA classification. Of note, TARA class A samples
laid at the extreme opposite to the non-TARA class A samples.
Although this association did not reach statistical significance
(A þ Aa versus all: c2 2.2, p ¼ 0.1), overall these data suggest a
link between BRAFmutational status and TARA classification.
No association between NRAS mutational status and TARA
classification was observed.
We next defined as “MAPKmutant” those samples carrying
either BRAF or NRAS mutation, and performed class compar-
ison between MAPKmutant and wild type samples. Five-hun-
dred-ninety-three genes were differentially expressed
between the two groups at a significance level of p < 0.01.
When using these genes to cluster the 113 melanoma metas-
tases, we found a tendency of the mutant samples to be asso-
ciated with TARA class A and Aa, though not absolutely.
Interestingly, these genes resulted once again to encode con-
stituents or regulators of the MAPK/ERK pathway.
We then sought to assess whether the association of BRAF
mutation with TARA classification was restricted to BRAF-
specific genes or whether it was dependent upon transcripts
associated with MAPK activation. Thus, we combined the lists
of genes obtained by the 3 class comparisons andwe found: 52
genes significantly deregulated in all the 3 gene lists (BRAF,
NRAS, MAPK), 107 genes NRAS-specific, 95 genes MAPK-
specific and 112 genes BRAF-specific. These sub-groups of
genes were further used to cluster the 113 melanoma metas-
tases (Figure 2).
Quite interestingly, the self-organizing heat map showed
that the expression of BRAF-specific genes was highly predic-
tive of the TARA classification (Figure 2b). Functional interpre-
tation of the 112 BRAF-specific transcripts ranked “Role of
JAK1, JAK2 andTYK2 in Interferon Signaling” as the top canon-
ical pathway (up regulated in wild type samples as compared
to themutant samples, Figure 2d) supporting the link between
BRAF mutation and immune phenotype. The hierarchical
cluster of melanoma metastases using the 112 BRAF specific
genes according to the BRAF status (excluding NRAS mutants
and samples uncertain after applying AS-PCR) was able to
clearly discriminate BRAF mutants versus WT samples
(Figure 2b, top panel).
We could not find any association between NRAS/MAPK
mutational status and TARA class when clustering the 113
metastases according to NRAS- and MAPK-specific genes,
respectively (Figure 2a), suggesting that the transcriptional
consequences resulting from mutation of BRAF and NRAS
are different, presumably through their differential capacity
to receive and transduce input signals through various effec-
tors. Moreover, some of the genes that discriminated BRAF
or NRASmutant samples were independent of the MAPK acti-
vation (112 and 107 genes were BRAF- and NRAS-specific,
respectively). This finding implies that some of the genes in
the BRAF discriminating gene list may not be necessarily the
direct targets of the transcription factors that are ultimatelyactivated by MAPKs. This hypothesis suggests that novel ther-
apeutic targets outside the MAPK pathway could be used to
treat melanoma carrying BRAF mutations.
In order to validate our findings, we used GSE22155 as an
independent dataset. GSE22155 included data from 57 mela-
noma metastases (28 BRAF mutated, 12 NRAS mutated and
17 wild type) defined as “high-immune”, “proliferative”,
“pigmentation” and “normal-like” based on a molecular clas-
sification (Jonsson et al., 2010). First, we determined whether
this classification was comparable to TARA classification. To
do so, we selected genes representative of both TARA A/
Th17 (IL17F, IL17B,WNT5A, IL17A) and TARA B/Th1 phenotype
(TYR, CCL5, CXCL10, GBP1, STAT1) (Spivey et al., 2012). The un-
supervised clustering clearly showed the high immune sam-
ples to behave similarly to TARA B/Th1 samples (expressing
TYR, CCL5, CXCL10, GBP1, STAT1) and the proliferative sam-
ples to behave similarly to TARA A/Th17 samples (expressing
IL17F, IL17B, WNT5A, IL17A, Figure 3a). As an additional proof,
we also plotted the GSE22155 samples in a PCA graph based on
the top 500 genes which were used to define TARA classes
(Figure 3b) and we found that such genes divided clearly the
high immune versus proliferative groups, allowing us to
consider these samples comparable to TARA B and TARA A,
respectively. When using the 112 BRAF specific transcripts
the high immune samples clearly distributed separately
compared to the proliferative ones, suggesting that the
BRAF-specific transcripts are indeed related to an immune
phenotype (Figure 3c).
3.5. The association between BRAF mutation and the
poor phenotype is stronger in samples displaying low BRAF
mRNA expression
We hypothesized that samples belonging to TARA class A and
Aa may have a stronger activation of the BRAF downstream
pathway through a higher BRAF mRNA expression. To test
this hypothesis, we divided the mutant metastases into
“high” and “low” according to the average BRAFmRNA expres-
sion among all mutant samples. Surprisingly and in discor-
dance with our hypothesis, we observed that, overall,
mutant TARA A and Aa samples displayed low BRAF expres-
sion while TARA B and Bb samples displayed high BRAF
expression (A þ Aa versus B þ Bb, Fisher’s exact test,
p ¼ 0.0009). Such an association was absolute when consid-
ering the only TARA A group, in other words all the A samples
displayed low BRAF expression (Figure 4a). We also tested
whether this association existed in wild type samples
(Supplementary Figure 3); even though we found a tendency
of low expressing mRNA BRAF samples to be TARA A and Aa
and high expressing mRNA BRAF samples to be TARA B and
Bb, such association did not reach statistical significance
(A þ Aa versus B þ Bb, Fisher’s exact test, p ¼ 0.09), suggesting
that the association between TARA classification and BRAF
mRNA expression is stronger in BRAF mutant samples.
In order to obtain insights about this intriguing finding, we
compared mutant samples expressing high and low levels of
BRAF mRNA versus the wild type samples. Class comparison
between BRAF mutant samples displaying high BRAF mRNA
expression and wild type samples identified only 418 tran-
scripts significantly deregulated at p < 0.01. When comparing
Figure 2 e Venn diagram and cluster of melanoma metastases (a) based on 95 MAPK-restricted transcripts (green), 52 MAPK-specific transcripts
(red) and 107 NRAS-specific transcripts (blue). Venn diagram and self-organizing heat map of 67 BRAF mutant and 20 BRAF wild type samples
based on 112 BRAF-specific transcripts (b, the heat map top legend refers to BRAF mutational status). Self-organizing heat map of the 113
metastases based on 112 BRAF-specific transcripts (c, the top legend refers to MAPK mutational status before and after AS-PCR, and TARA
classification). Functional interpretation analysis of the 112 BRAF-specific transcripts (d, green: down regulated in BRAF wild type samples, red:
up regulated in BRAF wild type samples).
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wild type samples, 2252 genes were significantly differentially
expressed at p < 0.01, suggesting that, overall, BRAF high
expressing samples are more similar to the wild type than
the BRAF low expressing samples. Finally, when comparing
low and high BRAF expressing mutant samples, we found
6296 transcripts differentially expressed at p < 0.01
(Figure 4). Functional interpretation analysis of these 6296
transcripts revealed several cancer-related pathways as well
as two immune-related pathways, namely, IL-2 and Jak/Stat
pathways (upregulated in high expressing BRAF samples;
Figure 4e).
BRAF small interference (siBRAF) experiment on 8 mela-
noma cell lines expressing high BRAF mRNA (higher than
the average BRAF mRNA expression) was performed to check
the expression of two genes previously associated to TARA
class B/Th1 phenotype, namely STAT1 and GBP1 (Spivey
et al., 2012). As expected, we could not find a reproducible
trend in the 8 “high” cell lines when BRAF was silenced
(Supplementary Figure 4), suggesting that the tumormicroenvironment plays an important role and cell lines do
not account for the complex interplay between tumor cells
and tumor microenvironment. Of note, 3 cell lines (3025,
2035 and 3104) had very low or absent GBP1 expression. Simi-
larly, the cell line 2035 had very low STAT1 expression; these
findings may be explained by the fact that the expression of
STAT1 and GBP1 may be driven by the immune or stromal
cells rather than by tumor cells (Galon et al., 2013; Jin et al.,
2014). It should be noted that we also assessed IL17A and
IL17B which are known to be expressed by Th17 lymphocytes;
expectably, we could not find any expression in the cell lines
tested (data not shown).4. Discussion
In the recent yearsmuchhas been learned about the biology of
BRAF and NRAS mutations in melanoma. However, what is
not clear yet is whether and how BRAF and NRAS mutations
affect the immune context of tumors. The availability of a
Figure 3 e Self-organizing map of GSE22155 dataset based on genes discriminative of TARA class A/Th1 phenotype and TARA class B/Th17
phenotype (a). PCA of GSE22155 dataset based on the 500 TARA specific transcripts (b). PCA and clustering of GSE22155 dataset based on the
112 BRAF specific genes (c).
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this point.
The sequencing of 113 melanomametastases showed that
59% and 12% were mutated in BRAF and NRAS genes, respec-
tively. These frequencies are in agreement with the reported
mutation rate in melanoma. No sample with BRAF mutation
also carried an NRAS mutation, which is in keeping with pre-
vious reports that have found BRAF and NRASmutations to be
almost mutually exclusive in a variety of cancer types (Brose
et al., 2002; Cohen et al., 2002; Davies et al., 2002; Kimura
et al., 2003). This suggests that BRAF and NRAS double mu-
tants not onlymay not provide an advantage for tumor growth
but they may even be selected against during tumorigenesis.
The genotyping of 15 paired cell lines and parental tumors
demonstrated discrepancies in BRAF/NRASmutation patterns
in 3 pairs, specifically 2 cell lines were BRAF V600E and one
NRAS Q61R while their corresponding tumors were wild
type, strongly suggesting that, in a fraction of cases, muta-
tions in these two genes might be acquired during progres-
sion. In order to exclude the possibility of low frequency
mutations in tumors we applied a highly sensitive allele-
specific PCR. Using this technique, the two tumors, assigned
previously as wild type by Sanger sequencing and whose cor-
responding cell linewas V600E, revealed in fact a BRAFmutant
phenotype. In contrast, the tumor from the tumor-cell line
pair discrepant for NRAS remained wild type after performingAS-PCR, suggesting that in this specific case the mutation in
the NRAS gene might have been acquired and become preva-
lent during culture expansion. On the other hand, discrepancy
in BRAF and NRAS mutation patterns have also been shown
between primary tumors and metastases (Colombino et al.,
2012), providing additional evidence thatmutations can be ac-
quired during tumor progression.
When assessing genes concordantly deregulated in BRAF
and NRAS mutant samples, we found that many of them
encoded constituents or regulators of the MAPK/ERK and
related pathways. In concordance with the findings of other
groups (Bloethner et al., 2005; Kannengiesser et al., 2008), the
set of genes prominently up regulated in mutant BRAF and
NRAS samples with a potential role, direct or indirect, in the
MAPK/ERK pathway included the dual specificity phosphatase
genes, DUSP4 and DUSP6; a serine protease inhibitor, SER-
PINE2; an inhibitor of MAPK signaling, SPRY2 and 14-3-3 bind-
ing proteins.
Initially, we postulated that there might be a common
MAPK activation signature (resulting from either BRAF or
NRAS mutation); however, we found no overabundance of
discriminatory genes for the combined group of samples dis-
playing either BRAF or NRAS mutations. This suggests that
the transcriptional consequences resulting from mutations
of BRAF or NRAS might be different, although there was over-
lapping of some genes, presumably due to their differential
Figure 4 e Cluster of melanoma metastases based on 112 BRAF-specific transcripts according to BRAF mutational status, TARA classification
and BRAF mRNA expression (a). Class comparisons between BRAF mutant HIGH versus wild type (WT, b), BRAF mutant LOW versus WT
(c), BRAF mutant HIGH versus LOW (d) at p< 0.01; “HIGH” and “LOW” refer to BRAF mRNA expression. Functional interpretation
analysis of 6296 genes discriminative of HIGH and LOW BRAF mRNA expression (e; green: down regulated in high expressing BRAF samples,
red: up regulated in high expressing BRAF samples).
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 9 3e1 0 4 101capacity to receive input signals and transduce them through
different effectors. This is in concordance with recent clinical
and preclinical studies which suggested that NRAS mutant
melanoma are characterized by patterns of signal transduc-
tion and biological behavior different from BRAF mutant mel-
anomas (Devitt et al., 2011; Fedorenko et al., 2012; Jakob et al.,
2012; Viros et al., 2008).
We further tested whether genes subsets specific for BRAF,
NRAS and MAPK activation were able to explain the different
phenotypes of melanoma metastases. Towards this goal, we
applied these specific genes to the melanoma metastases
and we surprisingly found that the 112 BRAF-specific genes
were highly predictive of TARA classification especially in
regards to TARA A samples.
Wewere not able to find the same associationwhen testing
NRAS- and MAPK-specific genes, suggesting that the only
BRAF-specific genes are able to explain the different biological
behaviors of the metastases.
The most crucial aspect of this study is, however, the
finding that the association between BRAF mutation and
TARA class A is particularly strong in cases in which BRAFmutation is present in tumors displaying low expression
levels of this gene. It may be likely that the mutation affects
the half-life of the protein, however, we cannot exclude that
the lower BRAF mRNA expression in the mutant samples is
due to a negative feedback loop established by the presence
of BRAF mutation.
Class comparison between BRAF mutant samples display-
ing high levels of BRAF mRNA expression and wild type sam-
ples revealed that there is much more similarity between the
two than with the low expressing BRAF mutant samples. To
gain further insights concerning this surprising finding we
performed functional interpretation analysis of 6296 genes
differentially expressed between BRAF mutants with high
and low expression of the same gene, deregulated pathways
included IL-2 and JAK/Stat signaling pathways, supporting
the immunoregulatory role of BRAF. Other reports have also
shown an immune-related role of BRAF mutation as essential
for cancer-immune evasion and able to promote stromal cell-
mediated immunosuppression via induction of IL-1 (Khalili
et al., 2012). A very recent investigation showed that the treat-
ment of metastatic melanoma patients with either BRAF
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 9 3e1 0 4102inhibitor alone or BRAF plus MEK inhibitor was associated to a
higher expression of melanoma antigens and to an overall
more favorable tumor microenvironment, further supporting
the implementation of combined BRAF targeted therapy and
immunotherapy (Frederick et al., 2013).
Studies thoroughly investigating the association between
BRAF/NRAS status and clinical response to immune-based
therapies are lacking. Joseph and colleagues (Joseph et al.,
2012) performed a retrospective analysis assessing the corre-
lation between clinical outcome and BRAF/NRAS mutation in
melanoma patients treated with IL-2. Patients with NRASmu-
tations were more likely to respond to IL-2 than wild type pa-
tients ( p ¼ 0.04). However, the advantage in term of overall
survival and progression-free survival did not reach the statis-
tically significance level ( p ¼ 0.30 and 0.13, respectively).
Although no significant association between BRAF and
outcome parameters was detected, the study was underpow-
ered to detect difference between BRAF andwild type patients.
Therefore, additional investigation assessing the predictive
role of BRAF and NRAS mutation in the context of immuno-
therapy (e.g. adoptive therapy, anti-CTLA4 and anti-PD1/PD-
1 ligands) are warranted.5. Conclusion
In conclusionwe provide novel insights into the effect of BRAF
and NRAS mutations on gene expression according to the im-
mune classification. However, gene expression analysis alone
cannot provide a comprehensive molecular understanding of
the mechanisms underlying such an association, thus further
deeper analyses are warranted to elucidate the mechanism
underlying the association of BRAF statuswith immunological
phenotypes (Tomei et al., 2014).
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